Clinical bottom line
Stem cell therapy represents a promising avenue for treating retinal degeneration, offering potential to restore or preserve vision by replacing damaged retinal cells or modulating the retinal microenvironment. Autologous induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) transplantation has demonstrated safety and preliminary efficacy in age-related macular degeneration (AMD). Advances in cell differentiation protocols, gene editing, and delivery methods continue to refine therapeutic potential. However, challenges remain regarding long-term functional integration, immunogenicity, and scalability. Current evidence supports cautious optimism, with ongoing clinical trials needed to establish durable benefits and safety profiles (Mandai et al., 2017; Temple et al., 2023).
What the evidence shows
Mandai et al. (2017) conducted a landmark first-in-human trial of autologous iPSC-derived RPE transplantation in AMD patients, demonstrating feasibility, safety, and some visual stabilization over 1 year. This study established proof-of-concept for personalized cell therapy in retinal degeneration.
Temple et al. (2023) review advances in cell therapy for neurodegenerative diseases, highlighting retinal degeneration as a key target. They emphasize innovations in stem cell differentiation, gene editing (e.g., CRISPR), and delivery techniques that enhance cell survival and integration.
Liu et al. (2022) summarize molecular pathology and biotherapeutic strategies in retinitis pigmentosa, underscoring the potential of stem cell approaches to replace photoreceptors and support retinal circuitry.
Ng et al. (2018) discuss stem cell therapy targeting retinal ganglion cell degeneration, a critical component in diseases like glaucoma, noting preclinical successes and translational challenges.
Huang et al. (2022) editorialize on stem cell-based retinal therapies, emphasizing the need for standardized protocols and long-term follow-up to assess functional outcomes and safety.
Sharma et al. (2021) provide a comprehensive review of stem cell therapy evidence to date, noting encouraging results in animal models and early-phase clinical trials but highlighting variability in methodologies and endpoints.
Caveats and uncertainty
Most clinical data derive from small, early-phase trials with limited follow-up.
Long-term survival, functional integration, and potential for tumorigenicity remain concerns.
Immunologic rejection risk persists despite autologous approaches.
Heterogeneity in retinal diseases and stages complicates patient selection and outcome interpretation.
Manufacturing scalability and regulatory hurdles challenge widespread clinical adoption.
How this may change practice
Stem cell therapy may evolve into a viable treatment option for select patients with retinal degeneration refractory to conventional therapies.
Multidisciplinary collaboration between ophthalmologists, stem cell biologists, and geneticists will be essential for patient selection and management.
Clinicians should counsel patients on the experimental nature of current therapies and the importance of clinical trial participation.
Advances in gene editing and personalized medicine may synergize with stem cell approaches to enhance efficacy.
Ongoing research will clarify optimal cell types, delivery methods, and timing to maximize functional recovery.